Resveratrol Ameliorated Hyperlipidemia: Association with Modulation of the Gut Microbiota and Bile Acid Metabolism.

Ruiying Luo, Qing Peng, Su Wu, Shuwen Liu, Chan Wang

Abstract read

In one paragraph

Article in Nutrients, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ruiying LuoNMPA Key Laboratory for Research and Evaluation of Drug Metabolism, Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.ORCID 0009-0008-8006-9484

Qing PengSchool of Pharmaceutical Sciences, South-Central Minzu University, Wuhan 430074, China.ORCID 0009-0007-5506-4131

Su WuNMPA Key Laboratory for Research and Evaluation of Drug Metabolism, Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.ORCID 0009-0002-5911-7003

Shuwen LiuNMPA Key Laboratory for Research and Evaluation of Drug Metabolism, Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.ORCID 0000-0001-6346-5006

Chan WangNMPA Key Laboratory for Research and Evaluation of Drug Metabolism, Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.

Funding

Guangzhou Institute of Science and Technology SL2023A04J00760National Natural Science Foundation of China 32202220

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Bile Acids and SaltsGastrointestinal MicrobiomeHyperlipidemiasHypolipidemic AgentsResveratrolAnimalsDiet, High-FatDisease Models, AnimalLiverMaleMiceMice, Inbred C57BLBile Acids and SaltsHypolipidemic AgentsResveratrolbile acidsgut microbiotahyperlipidemiaresveratrol

Identifiers

PMID42514453

DOI10.3390/nu18142384

PMCPMC13415314

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.